Allergan plc presented new analyses of VENUS II, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of ulipristal acetate (UPA), an investigational drug for the treatment of abnormal uterine bleeding in women with uterine fibroids.
“For a condition that affects an estimated 26 million women in the U.S.,1 there is a clear unmet medical need for new treatments for uterine fibroids,” said Millie A. Behera M.D., FACOG, Reproductive Endocrinology and Fertility Medical Director, Bloom Reproductive Institute in Arizona. “I am hopeful that, if approved, the availability of a once-daily oral medication like ulipristal acetate will encourage women to have a discussion with their doctor about their options to treat this condition.”
“Uterine fibroids are an indiscriminate disease that affect women regardless of their ethnicity or weight,” said David Nicholson, Ph.D., Chief Research and Development Officer, Allergan. “However, uterine fibroids are three times more common in women of African-American ancestry compared to Caucasian women,2 and the risk of developing fibroids steadily increases based on weight3.”
Three oral presentations were delivered at the American Society for Reproductive Medicine’s 73rd Annual Congress (ASRM 2017) in San Antonio, Texas.
About Allergan plc
Allergan plc headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.
Allergan’s success is powered by our more than 18,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com
CONTACTS:
Allergan:
Investors:
Daphne Karydas
(862) 261-8006
Media:
Mark Marmur
(862) 261-7558
Tara Schuh
(201) 427-8888
